ATE440097T1 - Substituierte hydantoine zur krebsbehandlung - Google Patents

Substituierte hydantoine zur krebsbehandlung

Info

Publication number
ATE440097T1
ATE440097T1 AT05784418T AT05784418T ATE440097T1 AT E440097 T1 ATE440097 T1 AT E440097T1 AT 05784418 T AT05784418 T AT 05784418T AT 05784418 T AT05784418 T AT 05784418T AT E440097 T1 ATE440097 T1 AT E440097T1
Authority
AT
Austria
Prior art keywords
cancer treatment
substituted hydantoins
hydantoins
substituted
cancer
Prior art date
Application number
AT05784418T
Other languages
English (en)
Inventor
Robert Goodnow
Nicholas Huby
Norman Kong
Lee Mcdermott
John Moliterni
Zhuming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE440097T1 publication Critical patent/ATE440097T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT05784418T 2004-09-17 2005-09-15 Substituierte hydantoine zur krebsbehandlung ATE440097T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61065504P 2004-09-17 2004-09-17
PCT/EP2005/009926 WO2006029862A1 (en) 2004-09-17 2005-09-15 Substituted hydantoins for the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE440097T1 true ATE440097T1 (de) 2009-09-15

Family

ID=35447646

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05784418T ATE440097T1 (de) 2004-09-17 2005-09-15 Substituierte hydantoine zur krebsbehandlung

Country Status (16)

Country Link
US (1) US7371869B2 (de)
EP (1) EP1791837B1 (de)
JP (1) JP4685873B2 (de)
KR (1) KR100869681B1 (de)
CN (1) CN101023079B (de)
AR (1) AR051290A1 (de)
AT (1) ATE440097T1 (de)
AU (1) AU2005284293B2 (de)
BR (1) BRPI0515371A (de)
CA (1) CA2579130A1 (de)
DE (1) DE602005016127D1 (de)
ES (1) ES2329264T3 (de)
MX (1) MX2007003166A (de)
RU (1) RU2393156C2 (de)
TW (1) TW200621766A (de)
WO (1) WO2006029862A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612212B2 (en) * 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
JP2010526848A (ja) * 2007-05-11 2010-08-05 エフ．ホフマン−ラ ロシュ アーゲー 難溶性薬物用の医薬組成物
ATE551336T1 (de) * 2007-08-16 2012-04-15 Hoffmann La Roche Substituierte hydantoine
JP2011506533A (ja) 2007-12-20 2011-03-03 エフ．ホフマン−ラ ロシュ アーゲー Ｍｅｋキナーゼ阻害剤としての置換ヒダントイン
US8993630B2 (en) 2008-11-10 2015-03-31 Bayer Intellectual Property Gmbh Substituted sulphonamido phenoxybenzamides
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
EP2491015A1 (de) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituierte benzosulfonamide
US20120269803A1 (en) 2009-10-21 2012-10-25 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
EP2491014A1 (de) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituierte halophenoxybenzamidderivate
AU2010313622B2 (en) 2009-11-02 2014-08-14 Ahr Pharmaceuticals, Inc. ITE for cancer intervention and eradication
US10632106B2 (en) 2009-11-02 2020-04-28 Ariagen, Inc. Methods of cancer treatment with 2-(1′H-Indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester
ES2576061T3 (es) 2010-02-25 2016-07-05 Dana-Farber Cancer Institute, Inc. Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF
BR112012022801B8 (pt) 2010-03-09 2019-10-29 Dana Farber Cancer Inst Inc método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
WO2012055953A1 (en) 2010-10-29 2012-05-03 Bayer Pharma Aktiengesellschaft Substituted phenoxypyridines
KR101472175B1 (ko) * 2012-02-17 2014-12-15 중앙대학교 산학협력단 신규한 2-아미노티아졸 유도체 및 이를 유효성분으로 포함하는 항암용 조성물
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
AU2015315132B2 (en) * 2014-09-12 2020-04-09 Ariagen, Inc. Efficient and scalable systhesis of 2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester and its structural analogs
RU2605091C2 (ru) * 2015-05-12 2016-12-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Казанский государственный медицинский университет" Министерства здравоохранения и социального развития" 2-амино-1-арил-5-(3,3-диметил-2-оксобутилиден)-4-оксо-n-(тиазол-5-ил)-4,5-дигидро-1н-пиррол-3-карбоксамиды, проявляющие противоопухолевую и антирадикальную активность, способ их получения и фармацевтическая композиция на их основе
CN108239083B (zh) 2016-12-26 2021-08-17 阿里根公司 芳香烃受体调节剂
EP3612531B1 (de) 2017-04-18 2022-08-24 Shanghai Fochon Pharmaceutical Co., Ltd. Apoptoseinduzierende mittel
EP3713937A2 (de) 2017-11-20 2020-09-30 Ariagen, Inc. Indolverbindungen als modulatoren des aryl-kohlenwasserstoff-rezeptors (ahr)
US10555558B2 (en) 2017-12-29 2020-02-11 Rai Strategic Holdings, Inc. Aerosol delivery device providing flavor control
IL287177B2 (en) 2019-04-15 2026-04-01 Ariagen Inc Indole-based chiral thiazole derivatives and their use
CN112341446B (zh) * 2019-08-09 2022-06-17 成都先导药物开发股份有限公司 一种免疫调节剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ501276A (en) 1997-07-01 2000-10-27 Warner Lambert Co 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders
KR19990012061A (ko) 1997-07-26 1999-02-25 성재갑 파네실 전이효소 저해제로 유용한 하이덴토인 유도체
AU5227001A (en) 2000-05-03 2001-11-12 Hoffmann La Roche Hydantoin-containing glucokinase activators
JP2004534857A (ja) * 2001-07-19 2004-11-18 フアルマシア・イタリア・エツセ・ピー・アー フェニルアセトアミド−チアゾール誘導体、それらの製造のための方法及び抗癌剤としてのそれらの使用
BRPI0514515A (pt) * 2004-08-17 2008-06-10 Hoffmann La Roche hidantoìnas substituìdas

Also Published As

Publication number Publication date
RU2393156C2 (ru) 2010-06-27
CA2579130A1 (en) 2006-03-23
MX2007003166A (es) 2007-05-15
BRPI0515371A (pt) 2008-07-22
JP2008513397A (ja) 2008-05-01
US20060063814A1 (en) 2006-03-23
EP1791837B1 (de) 2009-08-19
KR20070043895A (ko) 2007-04-25
TW200621766A (en) 2006-07-01
WO2006029862A1 (en) 2006-03-23
AU2005284293A1 (en) 2006-03-23
JP4685873B2 (ja) 2011-05-18
CN101023079A (zh) 2007-08-22
AU2005284293B2 (en) 2011-10-06
KR100869681B1 (ko) 2008-11-21
ES2329264T3 (es) 2009-11-24
AR051290A1 (es) 2007-01-03
CN101023079B (zh) 2010-05-05
US7371869B2 (en) 2008-05-13
RU2007114125A (ru) 2008-10-27
EP1791837A1 (de) 2007-06-06
DE602005016127D1 (de) 2009-10-01

Similar Documents

Publication Publication Date Title
ATE440097T1 (de) Substituierte hydantoine zur krebsbehandlung
IL197217B (en) Novel anti-cd38 antibodies for the treatment of cancer
DE602008005894D1 (de) Kondensierte imidazole zur krebsbehandlung
DE602005027052D1 (de) Endoskopbehandlungssystem
CY2200156T2 (el) Επεξεργασια λυματων
NO20070251A (no) Brønnbehandling
BRPI0810206A2 (pt) Método de tratar câncer
ATE435271T1 (de) Zusammensetzungen zur wäschebehandlung
ATE430187T1 (de) Zusammensetzungen zur wäschebehandlung
NO20070297A (no) Brønnbehandling
PT1937244T (pt) Tratamento do cancro com agonistas específicos de rxr
EP1967209A4 (de) Therapeutisches mittel gegen prostatakrebs
EP1718193A4 (de) Endoskop-anordnung
HUE054495T2 (hu) Rák kezelésére szolgáló készítmény
IL188430A0 (en) Treatment of tumors
DE602004021940D1 (de) Endoskopsystem
ATE404556T1 (de) Substituierte hydantoine
IL182993A0 (en) Treatment of mastitis
EP1949895A4 (de) Iontophorese-zubereitung
PT1830847E (pt) Tratamento para o cancro
DK1630309T3 (da) Afløb
DE602005021084D1 (de) ENDOSKOPisches BEHANDLUNGSSYSTEM
EP1765735A4 (de) Schlammbehandlungsverfahren
EP1789064A4 (de) Verbesserte krebsbehandlung
EP1745737A4 (de) Behandlungsinstrument für ein endoskop

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties